Is 0M2T undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6
Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 0M2T when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 0M2T (€0.75) is trading below our estimate of fair value (€1.92)
Significantly Below Fair Value: 0M2T is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 0M2T?
Key metric: As 0M2T is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
The above table shows the Price to Sales ratio for 0M2T. This is calculated by dividing 0M2T's market cap by their current
revenue.
What is 0M2T's PS Ratio?
PS Ratio
0.2x
Sales
€151.94m
Market Cap
€31.93m
0M2T key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Price-To-Sales vs Industry: 0M2T is good value based on its Price-To-Sales Ratio (0.2x) compared to the European IT industry average (0.9x).
Price to Sales Ratio vs Fair Ratio
What is 0M2T's PS Ratio
compared to its
Fair PS Ratio?
This is the expected PS Ratio taking into
account the company's forecast earnings growth, profit margins
and other risk factors.
0M2T PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio
0.2x
Fair PS Ratio
n/a
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 0M2T's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
The above table shows the analyst 0M2T forecast and predictions for the stock price in 12 month’s time.
Date
Share Price
Average 1Y Price Target
Dispersion
High
Low
1Y Actual price
Analysts
Current
n/a
€0.95
0%
5.3%
€1.00
€0.90
n/a
2
Nov ’25
€0.83
€0.95
+14.7%
5.3%
€1.00
€0.90
n/a
2
Oct ’25
n/a
€0.95
0%
5.3%
€1.00
€0.90
n/a
2
Sep ’25
€0.89
€0.95
+6.5%
5.3%
€1.00
€0.90
n/a
2
Aug ’25
n/a
€0.95
0%
5.3%
€1.00
€0.90
n/a
2
Jul ’25
€0.95
€1.14
+20.0%
21.1%
€1.38
€0.90
n/a
2
Jun ’25
n/a
€1.14
0%
21.1%
€1.38
€0.90
n/a
2
May ’25
n/a
€1.18
0%
19.5%
€1.41
€0.95
n/a
2
Apr ’25
n/a
€1.18
0%
19.5%
€1.41
€0.95
n/a
2
Mar ’25
n/a
€1.28
0%
25.5%
€1.60
€0.95
n/a
2
Sep ’24
€1.70
€3.50
+105.9%
11.4%
€3.90
€3.10
€0.89
2
Aug ’24
n/a
€3.50
0%
11.4%
€3.90
€3.10
n/a
2
Jul ’24
n/a
€3.95
0%
1.3%
€4.00
€3.90
€0.95
2
Jun ’24
n/a
€3.95
0%
1.3%
€4.00
€3.90
n/a
2
May ’24
n/a
€5.80
0%
32.8%
€7.70
€3.90
n/a
2
Apr ’24
n/a
€5.80
0%
32.8%
€7.70
€3.90
n/a
2
Mar ’24
n/a
€5.80
0%
32.8%
€7.70
€3.90
n/a
2
Feb ’24
n/a
€5.80
0%
32.8%
€7.70
€3.90
€1.22
2
Jan ’24
n/a
€5.40
0%
25.9%
€6.80
€4.00
€1.46
2
Dec ’23
n/a
€5.40
0%
25.9%
€6.80
€4.00
€1.34
2
Nov ’23
n/a
€5.77
0%
21.8%
€6.80
€4.00
n/a
3
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.